Overview
ZYME market data
Price History
ZYME price chart · 1M
- O
- 29.25
- H
- 29.48
- L
- 28.61
- C
- 29.16
- Vol
- 44,770.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $29.25
- Previous Close
- $29.32
- Day High
- $29.48
- Day Low
- $28.61
- 52 Week High
- $30.57
- 52 Week Low
- $21.68
- 7 Day Return
- +9.34%
- 30 Day Return
- +28.86%
- 90 Day Return
- +16.11%
- 1 Year Return
- +4.87%
- Daily Notional Volume
- $1.3M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.15 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -126.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.60 – $30.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.8B · P/B 7.39 · P/S 22.00.
Company News
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $38Benzinga · Aug 26, 2026, 3:39 PM
Zymeworks shares are trading higher after HC Wainwright & Co maintained its Buy rating on the stock and raised the price target from $51 to $55. Also, Citizens reiterated its Market Outperform rating and maintained a $32 price target.Benzinga · Aug 26, 2026, 2:26 PM
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On WednesdayBenzinga · Aug 26, 2026, 2:16 PM
MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · Aug 26, 2026, 1:26 PM
Citizens Reiterates Market Outperform on Zymeworks, Maintains $32 Price TargetBenzinga · Aug 26, 2026, 12:46 PM
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $55Benzinga · Aug 26, 2026, 10:12 AM
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer RegimensBenzinga · Aug 25, 2026, 4:51 PM
8-K filing — Zymeworks Inc. (ZYME)SEC EDGAR · Aug 25, 2026, 2:54 PM
Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unresectable Locally Advanced Or Metastatic Her2-Positive Gastroesophageal AdenocarcinomaBenzinga · Aug 25, 2026, 2:02 PM
B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44Benzinga · Aug 10, 2026, 5:19 PM